Neuronetics, Inc. (NASDAQ:STIM) CFO Stephen Furlong Sells 17,307 Shares

Neuronetics, Inc. (NASDAQ:STIM) CFO Stephen Furlong sold 17,307 shares of the stock in a transaction on Friday, February 14th. The shares were sold at an average price of $4.11, for a total value of $71,131.77. Following the sale, the chief financial officer now directly owns 454,420 shares in the company, valued at approximately $1,867,666.20. The trade was a 3.67 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Stephen Furlong also recently made the following trade(s):

• On Wednesday, February 12th, Stephen Furlong sold 10,845 shares of Neuronetics stock. The shares were sold at an average price of $3.83, for a total value of $41,536.35.
• On Monday, February 10th, Stephen Furlong sold 14,836 shares of Neuronetics stock. The stock was sold at an average price of $3.28, for a total value of $48,662.08.

Neuronetics Trading Up 14.7 %

NASDAQ:STIM traded up $0.64 during mid-day trading on Tuesday, reaching $5.00. The company’s stock had a trading volume of 3,620,915 shares, compared to its average volume of 1,700,355. The company’s fifty day simple moving average is $2.27 and its two-hundred day simple moving average is $1.43. The company has a debt-to-equity ratio of 4.90, a current ratio of 3.16 and a quick ratio of 2.87. Neuronetics, Inc. has a twelve month low of $0.52 and a twelve month high of $5.07. The stock has a market cap of $151.75 million, a P/E ratio of -4.07 and a beta of 2.17.

Institutional Trading of Neuronetics

A number of hedge funds have recently added to or reduced their stakes in STIM. GSA Capital Partners LLP boosted its stake in Neuronetics by 64.5% in the 3rd quarter. GSA Capital Partners LLP now owns 78,642 shares of the company’s stock worth $60,000 after buying an additional 30,837 shares during the last quarter. Landscape Capital Management L.L.C. acquired a new stake in Neuronetics in the 3rd quarter worth about $53,000. HighTower Advisors LLC boosted its stake in Neuronetics by 55.5% in the 3rd quarter. HighTower Advisors LLC now owns 245,982 shares of the company’s stock worth $187,000 after buying an additional 87,816 shares during the last quarter. David J Yvars Group boosted its stake in Neuronetics by 47.1% in the 4th quarter. David J Yvars Group now owns 46,325 shares of the company’s stock worth $75,000 after buying an additional 14,825 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its stake in Neuronetics by 10,954.1% in the 4th quarter. JPMorgan Chase & Co. now owns 54,939 shares of the company’s stock worth $88,000 after buying an additional 54,442 shares during the last quarter. 53.59% of the stock is owned by institutional investors and hedge funds.

Neuronetics Company Profile

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.